Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer. This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.

Trial Details

NCT ID
NCT07416240
Phase
EARLY_PHASE1
Sponsor
Hainan Cancer Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Claudin18.2 Targeted Activated Dendritic Cells
  • Claudin18.2 Targeted CAR-T Cells
Locations (sample)
  • Haikou, Hainan, China|20.03421,110.34651

Key Eligibility Criteria

  • Age ≥ 18 years, upper limit ≤ 80 years, gender not limited;
  • Participants must have a histologically or cytologically confirmed diagnosis of advanced pancreatic cancer, with at least one measurable lesion mee…
  • Tumor tissue positive for Claudin 18.2 by immunohistochemical detection (expression intensity ≥ 2+; expression range ≥ 50%);
  • Meeting the indications for PBMC collection and having no other contraindications for cell collection;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →